STAT

As pregnancy tech proliferates, women and their doctors wade through what’s helpful — and what’s a headache

As pregnancy tech proliferates, women and their doctors are wading through what’s helpful — and what’s a headache.

SAN FRANCISCO — Pregnancy care is poised for a 21st century upgrade.

Algorithms promise to detect the difference between real labor and a false alarm. Wearables give women a way to track contractions. Apps relay home blood pressure readings directly to doctors, offering a possible way to cut down on prenatal visits — and catch certain pregnancy complications before they become full-blown crises.

Doctors say the new technologies have the potential to transform prenatal care. But for all the promise, doctors caution that some direct-to-consumer devices might cause anxiety or unnecessary trips to the clinic — without strong evidence that they offer any real benefits to pregnant women.

“Prenatal care is burdensome. It requires patients to be in at minimum, once a month. People have jobs. It’s hard to get in… You could imagine some kind of virtual substitute would be very welcome,” said Dr. Thomas McElrath, an obstetrician-gynecologist at Brigham and Women’s Hospital in Boston. “But we would have to figure out and think carefully about how to do that,” he added.

Obstetrician-gynecologists are particularly worried about direct-to-consumer devices that aren’t woven into the fabric of prenatal care. Among their concerns: Faulty or confusing data might send women to their doctors when they don’t need to go. And for some devices, doctors say the lack of research or a true need to use them means they’re simply a waste of money.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Drug Shortages, Medicare Spending On An Alzheimer’s Drug, And More
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.

Related Books & Audiobooks